Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our many years of investment in both NGS and spatial sequencing now positions Singular to enter these high growth markets with a highly differentiated product |
| We believe the G4S will be uniquely able to serve these customers and accelerate growth within this space |
| Early collaborators included Catherine Wu from the Dana-Farber Cancer Institute, who noted the high sample throughput and excellent data quality that’s been generated on the G4X with our bone marrow samples, that tours via very difficult tissue types have been impressive and have allowed us to envision much larger studies that have not been previously possible |
| We are seeing strong interest from early collaborators, especially as it relates to our technology access services offering |
| And that combination is really resonating and it's just a very strong value proposition |
| We believe this is an area where we can offer novel and differentiated solutions with compelling business economics |
| We see a strong setup for the G4X to be a highly successful product and we are making the necessary trade-offs and decisions to invest and bring this product to market as fast as possible |
| Second, the business economics are attractive |
| Our NGS Foundation and continued innovation has resulted in a unique and powerful on ramp to spatial sequencing |
| First, strength of the value proposition |
| The ability to offer high throughput in the form of 10 to 40 tissue samples on a single flow cell translates to expected ASPs and margin dollars to be materially higher than current kits and significantly higher potential for consumable pullthrough for a G4X instrument |
| It was a productive quarter to finish off an important year for the company and I am pleased to update you on our progress |
| It's the novel ability to use sequencing in situ and do things like Direct-Seq and it's also the high throughput lower costs that our large imaging area will deliver |
| We commercially launched Max Read flow cell kits to customers for single cell sequencing increasing the output of the G4 to 800 million reads per flow cell or 3.2 billion reads per run for specific single cell in spatial sequencing applications We improved sequencing quality on the G4, recently increasing the specifications to 85% bases greater than or equal to Q30 |
| On spatial, the cost per sample and the ability to get anywhere from five to 40 samples on a single kit gives us the ability to potentially have ASPs that are many, many times higher on the same kit - on the same system with much higher margin dollars |
| We shipped eight G4 instruments during the quarter and generated $1.1 million in revenue, our highest quarterly total again |
| But I think one thing that we have learned is the service can be a really nice on ramp |
| So you can get to a point where you have really nice proof-of-concepts or really nice data, but productizing that and getting it out robustly |
| I'm excited as we look ahead to 2024 |
| In addition, we hosted a successful customer and KOL event, including lab directors and scientific leaders in the spatial community |
| What we're seeing on X is, we have a growing list, a dozen plus potential service collaborators that are in the funnel and that's growing very quickly |
| The g4x value proposition is expected to provide unique capabilities that customers are asking for |
| We are encouraged by the level of interest and engagement around the G4X |
| The conference generated more than 200 qualified marketing leads and now we have a growing pipeline of near-term service projects on the G4X and a funnel of potential sales opportunities for early adopters of the platform |
| In addition to our Q4 revenue performance, we had several other key accomplishments and activities for the year to note |
| While these actions were not easy we believed right-sizing the cost base of the organization was a necessary step to position us for success in the long term |
| We are encouraged by the feedback from early collaborators and interest from potential users coming out of AGBT |
| The spatial profiling in multiomic spaces in the early stages and is expected to grow rapidly |
| In total, we estimate the combined savings from these actions will reduce annualized operating expenses by approximately $20 million and extend our cash runway to late 2026 |
| But that Funnel on the services side is really starting to take shape nicely and we're executing on those now |
| Statement |
|---|
| Our gross margin was negative because of both additional discounts we provided to certain customers, as well as higher costs associated with the installation, training, and support of our system placements |
| Gross profit was negative $0.5 million in the fourth quarter of 2023, compared to approximately flat in the fourth quarter of 2022 |
| To this end, we recently made the difficult decision to reduce our headcount by approximately 20% and we reduce our spending plans to decrease cash burn and focus resource more heavily on our spatial sequencing product roadmap |
| We also recognize the need to manage our cash and resources preudently and have continued to identify and implement actions to drive additional cost savings |
| Not a problem |
| Net loss in the fourth quarter of 2023 was $23.2 million or $0.32 per share, compared to $21.1 million or $0.29 per share in the fourth quarter of 2022 |
| And then, lastly, so, as you continue to cut headcount to reduce cost, could you just talk about what you’re thinking about in terms of level of investment into the business to support the G4X launch? Drew Spaventa Yeah, the reductions are very difficult and we've been a lean operating company to the extent possible from onset |
| And that does require difficult and challenging trade-offs |
| Actual results may differ materially from those expressed or implied by these statements as a result of certain risks and uncertainties |
Please consider a small donation if you think this website provides you with relevant information